Available Technology

T-Cell Enumeration Using Dried Blood Spots as a Surrogate for CD4+ T-Cell Counts to Monitor HIV+ Patients

Available for licensing and commercial development is a novel method for enumerating T-cells in HIV+ patients using dried blood spots, avoiding the need for fresh blood samples. The method relies on the distinctive nature of the TCR-beta gene, which undergoes a rearrangement during T-cell development that is required to produce a functional T-cell receptor protein. Since only mature T-cells contain a rearranged TCR-beta gene, the method quantifies the number of T-cells in a patient sample by quantifying the number of cells that contain a rearranged TCR-beta gene. In addition to dried blood spots, the assay can be also used with a wide variety of sample types from which T-cell counts were previously impossible to obtain, such as swabs and tissue slides. In addition, this method can be used for monitoring of a variety of T-cell leukemias/lymphomas, and easily adapted to monitor B-cell levels found in B-cell leukemias/lymphomas. The assay was found to accurately predict TCR-beta levels (r=0.985, p
Abstract: 
Available for licensing and commercial development is a novel method for enumerating T-cells in HIV+ patients using dried blood spots, avoiding the need for fresh blood samples. The method relies on the distinctive nature of the TCR-beta gene, which undergoes a rearrangement during T-cell development that is required to produce a functional T-cell receptor protein. Since only mature T-cells contain a rearranged TCR-beta gene, the method quantifies the number of T-cells in a patient sample by quantifying the number of cells that contain a rearranged TCR-beta gene. In addition to dried blood spots, the assay can be also used with a wide variety of sample types from which T-cell counts were previously impossible to obtain, such as swabs and tissue slides. In addition, this method can be used for monitoring of a variety of T-cell leukemias/lymphomas, and easily adapted to monitor B-cell levels found in B-cell leukemias/lymphomas. The assay was found to accurately predict TCR-beta levels (r=0.985, p
Patent Number: 
61/131,954
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin